18
|
99
|
3sabA |
Crystal structure of wild-type hiv-1 protease in complex with af78 |
99
|
387
|
3s7mA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
18
|
99
|
3sa9A |
Crystal structure of wild-type hiv-1 protease in complex with af68 |
102
|
387
|
3s7lA |
Pyrazolyl and thienyl aminohydantoins as potent bace1 inhibitors |
18
|
99
|
3s53A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p212121 |
90
|
387
|
3rviA |
Structure of bace-1 (beta-secretase) in complex with 2-((2-amino-6-o-tolylquinolin-3-yl)methyl)-n-(cyclohexylmethyl)pentanamide |
18
|
99
|
3s43B |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
16
|
99
|
3s45A |
Wild-type hiv-2 protease with antiviral drug amprenavir |
88
|
387
|
3s2oA |
Fragment based discovery and optimisation of bace-1 inhibitors |
17
|
99
|
3s56A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug saquinavir |
88
|
387
|
3ru1A |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-(cyclohexylmethyl)propanamide |
19
|
99
|
3s54A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug darunavir in space group p21212 |
19
|
99
|
3s43A |
Hiv-1 protease triple mutants v32i, i47v, v82i with antiviral drug amprenavir |
94
|
387
|
3rsxA |
Structure of bace-1 (beta-secretase) in complex with 6-(thiophen-3-yl)quinolin-2-amine |
91
|
387
|
3rtmA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-aminoquinolin-3-yl)-n-cyclohexyl-n-methylpropanamide |
88
|
387
|
3rsvA |
Structure of bace-1 (beta-secretase) in complex with (r)-3-(2-amino-6-o-tolylquinolin-3-yl)-n-((r)-2,2-dimethyltetrahydro-2h-pyran-4-yl)-2-methylpropanamide |
90
|
387
|
3rthA |
Structure of bace-1 (beta-secretase) in complex with 6-(2-(3,3-dimethylbut-1-ynyl)phenyl)quinolin-2-amine |
92
|
387
|
3rtnA |
Structure of bace-1 (beta-secretase) in complex with 3-(2-amino-6-o-tolylquinolin-3-yl)-n-cyclohexylpropanamide |
84
|
330
|
3lzyA |
Crystal structure of endothiapesin in complex with xenon |
78
|
329
|
2vs2A |
Neutron diffraction structure of endothiapepsin in complex with a gem- diol inhibitor. |
18
|
99
|
5upjA |
Hiv-2 protease/u99283 complex |
91
|
389
|
5tolA |
Crystal structure of beta-site app-cleaving enzyme 1 complexed with n-(3-((4as,7as)-2-amino-4,4a,5,6-tetrahydro-7ah-furo[2,3-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-bromo-2-pyridinecarboxamide |
82
|
339
|
5t4sA |
Novel approach of fragment-based lead discovery applied to renin inhibitors |
86
|
339
|
5sy2A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
89
|
337
|
5sy3A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
87
|
337
|
5sz9A |
Structure-based design of a new series of n-piperidin-3-ylpyrimidine-5-carboxamides as renin inhibitors |
82
|
330
|
5p7mA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 319 |
83
|
330
|
5p39A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 162 |
84
|
330
|
5p3iA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 171 |
82
|
330
|
5p6uA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 291 |
83
|
330
|
5p1yA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 117 |
82
|
330
|
5p8jA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 352 |
84
|
330
|
5p3aA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 163 |
84
|
330
|
5p5tA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 254 |
82
|
330
|
5p22A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 120 |
84
|
330
|
5p77A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 304 |
84
|
330
|
5p3rA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 180 |
82
|
330
|
5p8cA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 345 |
83
|
330
|
5p4fA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 204 |
83
|
330
|
5p7cA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 309 |
82
|
330
|
5p8sA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 361 |
83
|
330
|
5p5fA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 240 |
84
|
330
|
5p5sA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 253 |
83
|
330
|
5p11A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 84 |
83
|
330
|
5p6iA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 279 |
83
|
330
|
5p1zA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 118 |
84
|
330
|
5p81A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 334 |
84
|
330
|
5p3kA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 173 |
84
|
330
|
5p3tA |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 182 |
84
|
330
|
5p52A |
Automated refinement of diffraction data obtained from an endothiapepsin crystal treated with fragment 227 |